Clinical trials: Candidates for Systemic Therapy for Psoriasis
Chronic Plaque Psoriasis
Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy
A study to assess the safety and efficacy of 2 different doses of CDP870 versus placebo, administered during 12 weeks, to patients suffering from moderate to severe chronic plaque psoriasis, extended by a 12 to 24 week follow-up.
- Trial name
- NCT00245765
- Testing
- Certolizumab Pegol
- Where
- 15 sites in France, Germany
- Volunteers
- 176 people
- Sponsor
- UCB Pharma
Psoriasis
Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques.
- Trial name
- NCT04908475
- Testing
- Risankizumab, Apremilast
- Where
- 54 sites in United States, Canada and 3 more
- Volunteers
- 352 people
- Sponsor
- AbbVie
Psoriasis
Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis
The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 [NCT00245765] and Week 12 of re-treatment in this study.
- Trial name
- NCT00329303
- Testing
- Certolizumab Pegol (Cimzia®)
- Where
- 14 sites in France, Germany
- Volunteers
- 71 people
- Sponsor
- UCB Pharma
Candidates for Systemic Therapy for Psoriasis, Psoriasis
A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis
An open-label, multi-center study to establish psoriasis control of moderate to severe plaque psoriasis with Raptiva therapy administered subcutaneously for 24 weeks.
- Trial name
- NCT00287118
- Testing
- Efalizumab
- Where
- Switzerland
- Volunteers
- 189 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psoriasis
A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies
This is a Phase IIIb/IV, open label, multicentre study of efalizumab (anti cluster of differentiation [CD] 11a recombinant human monoclonal antibody) in participants with moderate to severe plaque psoriasis who have failed to…
- Trial name
- NCT00249808
- Testing
- Efalizumab - anti-CD11a recombinant human monoclonal antibody
- Where
- United Kingdom
- Volunteers
- 1,266 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psoriasis
Psoriasis Longitudinal Assessment and Registry
The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque and other forms of psoriasis.
- Trial name
- PSOLAR (NCT00508547)
- Where
- 320 sites in United States, Argentina and 20 more
- Volunteers
- 20,167 people
- Sponsor
- Janssen Scientific Affairs, LLC
Psoriasis
A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to compare the efficacy of Guselkumab with commercially available active comparator Fumaderm initial/Fumaderm tablets for the treatment of adult participants with moderate to severe plaque-type…
- Trial name
- POLARIS (NCT02951533)
- Testing
- Guselkumab, Fumaric Acid Esters
- Where
- 28 sites in Germany
- Volunteers
- 119 people
- Sponsor
- Janssen-Cilag G.m.b.H
Moderate Plaque Psoriasis
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and abdomen).
- Trial name
- IMMpactful (NCT06333860)
- Testing
- Risankizumab, Deucravacitinib
- Where
- 88 sites in United States, Australia and 10 more
- Volunteers
- 393 people
- Sponsor
- AbbVie
Psoriasis
A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy
The purpose of this study is to compare the efficacy and safety of subcutaneous (SC) risankizumab and oral FUMADERM provided as study medication in participants with moderate to severe plaque psoriasis who are naïve to and…
- Trial name
- NCT03255382
- Testing
- Fumaderm, risankizumab
- Where
- 23 sites in Germany
- Volunteers
- 120 people
- Sponsor
- AbbVie
Chronic Plaque Psoriasis
A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis
This is a phase 2, randomized, placebo-controlled, 2-period study to evaluate the safety, tolerability, and efficacy of belumosudil in adult subjects with moderate to severe chronic plaque psoriasis who are candidates for…
- Trial name
- NCT02852967
- Testing
- Belumosudil
- Where
- 14 sites in United States
- Volunteers
- 110 people
- Sponsor
- Kadmon Corporation, LLC
Psoriasis
Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
The main objective of this study is to evaluate the efficacy and safety of risankizumab compared with secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic…
- Trial name
- NCT03478787
- Testing
- risankizumab, secukinumab
- Where
- 61 sites in United States, Canada and 7 more
- Volunteers
- 327 people
- Sponsor
- AbbVie
Psoriasis
Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis
Our laboratory is studying a skin disease known as psoriasis. The purpose of this protocol is to study the action and the effects of Efalizumab, on psoriasis.
- Trial name
- NCT00115076
- Testing
- Efalizumab
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Rockefeller University
Psoriasis
A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
This is a Phase IIIb, randomized, double-blind, parallel-group, placebo-controlled, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in…
- Trial name
- NCT00109317
- Testing
- Raptiva (efalizumab)
- Volunteers
- 686 people
- Sponsor
- Genentech, Inc.
Psoriasis
LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis
Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis
- Trial name
- NCT03254667
- Testing
- Brodalumab, Comparator Drug (non-biologic IL-17 inhibitors)
- Where
- United States
- Volunteers
- 3,500 people
- Sponsor
- Bausch Health Americas, Inc.
Ankylosing Spondylitis, Autoimmune Disease
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs.
- Conditions
- Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Enteropathic Arthritis
- Trial name
- NCT04751396
- Testing
- Best Practice, Educational Intervention, Interview
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- M.D. Anderson Cancer Center